Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 6.66%.
ENDO INTL PLC Price and EPS Surprise
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Endo surpassed third-quarter 2016 earnings. The company reported EPS of $1.01 while our consensus called for EPS of 81 cents.
Revenues Beat: Revenues also came in above expectations. Endo posted revenues of $884.3 million, compared to our consensus estimate of $867 million.
2016 Guidance Maintained: Endo reiterated its outlook for 2016. The company continues to expect revenues in the range of $3.87 billion to $4.03 billion. It still expects earnings in the range of $4.50 to $4.80 per share. The Zacks Consensus Estimate for earnings is $4.55 per share on revenues of $3.91 billion in 2016.
Pre-Market Trading: Shares are up around 7% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Image: Bigstock
Endo (ENDP) Beats Earnings & Revenue Estimates in Q3
Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 6.66%.
ENDO INTL PLC Price and EPS Surprise
ENDO INTL PLC Price and EPS Surprise | ENDO INTL PLC Quote
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Endo surpassed third-quarter 2016 earnings. The company reported EPS of $1.01 while our consensus called for EPS of 81 cents.
Revenues Beat: Revenues also came in above expectations. Endo posted revenues of $884.3 million, compared to our consensus estimate of $867 million.
2016 Guidance Maintained: Endo reiterated its outlook for 2016. The company continues to expect revenues in the range of $3.87 billion to $4.03 billion. It still expects earnings in the range of $4.50 to $4.80 per share. The Zacks Consensus Estimate for earnings is $4.55 per share on revenues of $3.91 billion in 2016.
Pre-Market Trading: Shares are up around 7% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>